title: Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
abstract: Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical cancer. In this study, we demonstrate that dendritic cells (DCs) pulsed with HPV16 E7 protein are not only recognized in vitro by E7-specific CTLs but also elicit E7-specific CTL responses in vivo, associated with protection against a challenge with syngeneic HPV16-induced tumor cells. Vaccination with soluble E7 protein in incomplete Freund's adjuvant likewise induces E7-specific CTL responses associated with tumor protection. The presence of HPV16 E7-specific CTLs in vivo and the observation that depletion of CD8+ cells completely abolishes tumor protection demonstrate that CTLs are the major effector cells in mediating antitumor activity. The in vivo involvement of DCs in the activation of protective CTLs is suggested by the surface display of E7 peptide-loaded MHC class I molecules on these cells after E7 protein immunization. These data show that HPV16 E7 protein-pulsed DCs, as well as the administration of E7 protein antigen in adjuvant, can effectively stimulate tumor-specific MHC class I-restricted CD8+ T-cell-mediated protective immunity to HPV16-induced cancers.
authors.affiliation: Department of Immunohematology and Blood Bank, University Hospital Leiden, The Netherlands.
authors.forename: M L
authors.initials: ML
authors.lastname: De Bruijn
authors.forename: D H
authors.initials: DH
authors.lastname: Schuurhuis
authors.forename: M P
authors.initials: MP
authors.lastname: Vierboom
authors.forename: H
authors.initials: H
authors.lastname: Vermeulen
authors.forename: K A
authors.initials: KA
authors.lastname: de Cock
authors.forename: M E
authors.initials: ME
authors.lastname: Ooms
authors.forename: M E
authors.initials: ME
authors.lastname: Ressing
authors.forename: M
authors.initials: M
authors.lastname: Toebes
authors.forename: K L
authors.initials: KL
authors.lastname: Franken
authors.forename: J W
authors.initials: JW
authors.lastname: Drijfhout
authors.forename: T H
authors.initials: TH
authors.lastname: Ottenhoff
authors.forename: R
authors.initials: R
authors.lastname: Offringa
authors.forename: C J
authors.initials: CJ
authors.lastname: Melief
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D005620:Freund's Adjuvant / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000472:pathogenicity*; D050725:Papillomavirus E7 Proteins; D014412:Tumor Virus Infections / Q000517:prevention & control*
chemical_list: D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D005620:Freund's Adjuvant